You are here

Canada House Builds on Sales License with Clinic Expansion in Fredericton

TORONTO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (“Canada House” or the “Company”) (CSE:CHV) is pleased to announce the January 21st opening in Fredericton of its eleventh medical cannabis clinic under its wholly owned subsidiary, Canada House Clinics Inc. (“CHC”). The clinic is located downtown in New Brunswick’s capital city at 140 King Street.

CHC is committed to helping many more Canadians improve their physical and mental health with personalized medical cannabis treatment plans. Each of the CHC locations across Canada offer highly trained nurses working as Cannabinoid Therapy Educators as well as licensed and specially trained Prescribers.   The clinics support patients through education, specialized treatment plans, medical documents, licensed producer registration and ongoing support.  

“CHC will be opening additional clinics in 2019 in major cities across Canada to supplement its existing network of clinics near military bases,” said Canada House CEO Chris Churchill-Smith. “CHC is committed to those Canadians wanting to discuss cannabinoid therapy in a clinic setting while also providing full telemedicine options.”

The historical placement of CHC clinics near military bases was for the founding mission to help alleviate the suffering of veterans struggling with their operational stress injuries.  With a broader cross-section of Canadians coming to CHC locations for years for common to complex medical conditions, Canada House Clinics is committed to opening additional locations in larger urban centers while also continuing to support veterans.

As part of improving access for more Canadians, Canada House will also be relocating its Moncton clinic in February to a more convenient and central location.

Canada House Wellness Group Inc.

Canada House is an experienced, integrated medical cannabis company providing patient-specific cannabinoid therapy products and services through its clinics and licensed producer. Canada House is the parent company of Canada House Clinics Inc., Knalysis Technologies and Abba Medix Corp. For more information, please visit www.canadahouse.ca or www.sedar.com.

For further information, please contact:

Boom Capital Markets
Steve Low
647-620-5101
steve@boomcapitalmarkets.com

Canada House Wellness Group Inc.
Chris Churchill-Smith, CEO
514-313-0102
chris.smith@canadahouse.ca

Cautionary Statement Regarding Forward-Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Monday, January 14, 2019 - 07:30